COST-UTILITY OF PNEUMOCOCCAL VACCINATION STRATEGIES FOR ADULTS AGED 50 AND OLDER IN COLOMBIA: A MODEL-BASED ECONOMIC EVALUATION
Author(s)
Jaime Ordoñez, MEd, PhD;
TrueConsulting, MEDELLIN, Colombia
TrueConsulting, MEDELLIN, Colombia
OBJECTIVES: To evaluate the cost-utility of available pneumococcal vaccination strategies for Colombian adults aged ≥50 years, comparing medium-term (5-year) and long-term (10-year) time horizons from the public health system perspective.
METHODS: A decision-tree model simulated a cohort of healthy adults aged 50 years or older receiving one of six vaccination strategies (strategies involve pneumococcal conjugate vaccines - PCV and Pneumococcal polysaccharide vaccine - PPSV23) or no vaccination. Age-specific incidence from Colombia, mortality, costs, and quality-adjusted life years (QALYs) were included. Two-time horizons (5 year and 10 years) were modeled and a discount rate of 5% for costs and health benefits was applied. Vaccine efficacy was derived from published clinical trials, however, PPSV23 efficacy in pneumococcal pneumonia was assumed to be negligible as recent evidence does not support a significant effect. Serotype coverage by vaccine was extracted from the Colombian National Institute of Health, with the highest coverages among adults obtained in PCV20 and PPSV23 with 60.3% and 64.2% respectively. Probabilistic sensitivity analyses and cost-effectiveness acceptability curves were used to assess uncertainty.
RESULTS: PCV13, PCV15, PCV20 and PCV13 + PPSV23 were cost-effective against no intervention at a 10-year horizon (ICERs: $2,112; $7,630; $2,516 and $8,003 per QALY, respectively), with PCV20 having the highest probability of being the most cost-effective strategy (73.4% at a $8,266 willingness-to-pay threshold). Also, PCV20 could prevent the most significant number of pneumococcal disease cases, deaths, and complications over the model horizon (1,427 deaths averted). PPSV23 and PCV15+PPSV23 strategies were less effective and more costly over time.
CONCLUSIONS: All the strategies that involve conjugated vaccines were cost-effective against no-intervention. Nevertheless, PCV20 offers the most favorable economic and health impact among pneumococcal vaccination strategies for Colombian adults aged 50 years and older. Its use would maximize health gains, reduce healthcare costs over time, and support efficient resource allocation within the Colombian health system.
METHODS: A decision-tree model simulated a cohort of healthy adults aged 50 years or older receiving one of six vaccination strategies (strategies involve pneumococcal conjugate vaccines - PCV and Pneumococcal polysaccharide vaccine - PPSV23) or no vaccination. Age-specific incidence from Colombia, mortality, costs, and quality-adjusted life years (QALYs) were included. Two-time horizons (5 year and 10 years) were modeled and a discount rate of 5% for costs and health benefits was applied. Vaccine efficacy was derived from published clinical trials, however, PPSV23 efficacy in pneumococcal pneumonia was assumed to be negligible as recent evidence does not support a significant effect. Serotype coverage by vaccine was extracted from the Colombian National Institute of Health, with the highest coverages among adults obtained in PCV20 and PPSV23 with 60.3% and 64.2% respectively. Probabilistic sensitivity analyses and cost-effectiveness acceptability curves were used to assess uncertainty.
RESULTS: PCV13, PCV15, PCV20 and PCV13 + PPSV23 were cost-effective against no intervention at a 10-year horizon (ICERs: $2,112; $7,630; $2,516 and $8,003 per QALY, respectively), with PCV20 having the highest probability of being the most cost-effective strategy (73.4% at a $8,266 willingness-to-pay threshold). Also, PCV20 could prevent the most significant number of pneumococcal disease cases, deaths, and complications over the model horizon (1,427 deaths averted). PPSV23 and PCV15+PPSV23 strategies were less effective and more costly over time.
CONCLUSIONS: All the strategies that involve conjugated vaccines were cost-effective against no-intervention. Nevertheless, PCV20 offers the most favorable economic and health impact among pneumococcal vaccination strategies for Colombian adults aged 50 years and older. Its use would maximize health gains, reduce healthcare costs over time, and support efficient resource allocation within the Colombian health system.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE193
Topic
Economic Evaluation
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), STA: Vaccines